Mugglehead
Subscribe

Medtronic plans US$380M Contego Medical acquisition for vascular portfolio

The proposed purchase adds carotid and clot-removal devices, with possible later payments and closing expected in Medtronic's fiscal third quarter.

Adrian Kessler·
An oversized stethoscope rests in the courtyard of a generic outpatient medical centre.
An oversized stethoscope in a medical centre courtyard illustrates a proposed vascular-device acquisition. Illustration: Mugglehead, generated with AI.

A US$380 million acquisition would broaden the carotid-artery and clot-removal portfolio of Medtronic plc NYSEMDT after it announced plans on Monday to buy privately held Contego Medical, Inc. Medtronic expects a small reduction in adjusted earnings per share in fiscal 2027 and 2028.

The Nov. 16 announcement puts the transaction's value at US$380 million, with potential payments after the acquisition. It gives neither the amounts nor the triggers for those later payments, and expects completion in Medtronic's fiscal third quarter, subject to customary closing conditions.

Medtronic is a large medical technology company headquartered in Galway, Ireland, supplying cardiovascular devices, surgical tools and patient-monitoring systems worldwide.

Shares closed at US$102.86 in New York at 4:00 p.m. EST on Nov. 13 NYSEMDT. That close predates the acquisition announcement and provides no measure of the market's response to the proposed purchase.

Contego Adds Carotid And Clot-Removal Devices

The purchase would build on an exclusive U.S. distribution agreement announced in January 2025. Medtronic describes the proposed acquisition as a targeted investment in its core franchises, broadening its carotid technologies alongside its peripheral vascular treatments.

The deal announcement does not specify a cash-and-share split, a financing arrangement or a break fee. It also gives no quantified revenue contribution or cost-savings target, leaving the purchase price without a disclosed sales multiple. The release identifies no specific regulatory approvals among the customary conditions it cites.

Read more: Medtronic spin-out MiniMed lists on Nasdaq, attains EU approval for diabetes tech

The assets include Contego's Neuroguard IEP Direct System for transcarotid artery revascularization, a procedure to restore blood flow through a narrowed carotid artery. Contego's product description combines a stent, balloon and filter in one system, with blood-flow reversal providing another element of protection.

Carotid artery disease narrows or blocks the vessels supplying the brain. Medtronic says debris released during treatment can contribute to procedural stroke risk, which Contego's integrated embolic-protection technology is designed to address.

"Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures," Contego founder and chief executive Ravish Sachar said in the announcement.

The proposed purchase also includes Contego's Excipio thrombectomy devices. Medtronic says those devices would complement its Liberant system for treating peripheral vascular disease, adding another product line beyond the carotid portfolio.

Read more: Medtronic reports 88.1 per cent ulcer healing in two-year VenaSeal study

Boston Scientific Already Owns A Carotid Platform

Boston Scientific Corporation NYSEBSX offers a direct acquisition comparison through its Sept. 17, 2024 purchase of Silk Road Medical. That transaction brought a transcarotid artery revascularization platform into Boston Scientific's vascular business at an enterprise value of approximately US$1.18 billion.

Boston Scientific's closing announcement expected an immaterial adjusted earnings effect in 2024 and 2025, followed by accretion. Medtronic's forecast calls for two fiscal years of slight dilution before a neutral or positive contribution.

Medtronic does not put a number on the expected earnings reduction. Its Nov. 16 release forecasts a neutral or positive contribution to adjusted earnings per share after fiscal 2028.

The iShares U.S. Medical Devices ETF NYSEARCAIHI traded at US$58.02 at 8:00 p.m. EST on Nov. 13. That sector reading also predates the Contego announcement.

Medtronic has scheduled its next results for Nov. 24, covering the quarter ended Oct. 30. The report will show operating performance before the planned fiscal third-quarter acquisition closing.

More in Health & Science

View all